{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:38:40Z","timestamp":1783953520202,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515030299"],"award-info":[{"award-number":["2024A1515030299"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["202404"],"award-info":[{"award-number":["202404"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["JCYJ20230807145859002"],"award-info":[{"award-number":["JCYJ20230807145859002"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004433","name":"Chinese Pharmaceutical Association","doi-asserted-by":"publisher","award":["CPA-Z05-ZC-2024-003"],"award-info":[{"award-number":["CPA-Z05-ZC-2024-003"]}],"id":[{"id":"10.13039\/501100004433","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.dmd.2025.100090","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T19:13:11Z","timestamp":1746213191000},"page":"100090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["ABCC2 as a novel covariate influencing oxcarbazepine pharmacokinetics in pediatric epilepsy: Insights from population modeling"],"prefix":"10.1016","volume":"53","author":[{"given":"Xianhuan","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9585-0398","authenticated-orcid":false,"given":"Jiahao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8318-6936","authenticated-orcid":false,"given":"Yaodong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2506-6324","authenticated-orcid":false,"given":"Wenzhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmd.2025.100090_bib1","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-3908","article-title":"Incidence and prevalence of childhood epilepsy: a nationwide cohort study","volume":"139","author":"Aaberg","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.dmd.2025.100090_bib2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics","volume":"48","author":"Anderson","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"Suppl 1","key":"10.1016\/j.dmd.2025.100090_bib3","first-page":"S42","article-title":"Characterization of the ontogeny of hepatic UDP-glucuronosyltransferase enzymes based on glucuronidation activity measured in human liver microsomes","volume":"59","author":"Bad\u00e9e","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100090_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1684\/epd.2015.0736","article-title":"Incidence, prevalence and aetiology of seizures and epilepsy in children","volume":"17","author":"Camfield","year":"2015","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.dmd.2025.100090_bib5","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/jcpt.12792","article-title":"Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy","volume":"44","author":"Chen","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.dmd.2025.100090_bib6","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/17512433.2021.1917377","article-title":"Population pharmacokinetics of oxcarbazepine: a systematic review","volume":"14","author":"Chen","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100090_bib7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev-pharmtox-033020-113257","article-title":"Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy","volume":"61","author":"Darwich","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.dmd.2025.100090_bib8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2165\/00003088-199936060-00005","article-title":"Glucuronidation in humans. Pharmacogenetic and developmental aspects","volume":"36","author":"de Wildt","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmd.2025.100090_bib9","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1517\/14656566.8.10.1415","article-title":"Parent drug and\/or metabolite? Which of them is most appropriate to establish bioequivalence of two oral oxcarbazepine formulations in healthy volunteers?","volume":"8","author":"Di Girolamo","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.dmd.2025.100090_bib10","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.dmd.2025.100090_bib11","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00228-020-03080-y","article-title":"Population pharmacokinetics of unbound valproic acid in pediatric epilepsy patients in China: a protein binding model","volume":"77","author":"Gu","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100090_bib12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/FPC.0b013e3282f974b7","article-title":"Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol","volume":"18","author":"Haenisch","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.dmd.2025.100090_bib13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2174\/138945011795378487","article-title":"Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition","volume":"12","author":"Haufroid","year":"2011","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.dmd.2025.100090_bib14","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/jps.23574","article-title":"A pharmacokinetic standard for babies and adults","volume":"102","author":"Holford","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.dmd.2025.100090_bib15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.canlet.2005.06.051","article-title":"Implications of genetic polymorphisms in drug transporters for pharmacotherapy","volume":"234","author":"Kerb","year":"2006","journal-title":"Cancer Lett"},{"key":"10.1016\/j.dmd.2025.100090_bib16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/FPC.0b013e328338073a","article-title":"A nonsynonymous variation in MRP2\/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy","volume":"20","author":"Kim","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.dmd.2025.100090_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.eplepsyres.2005.11.011","article-title":"Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis","volume":"68","author":"Kubota","year":"2006","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.dmd.2025.100090_bib18","first-page":"487","article-title":"Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years","volume":"47","author":"Li","year":"2009","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"10.1016\/j.dmd.2025.100090_bib19","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1007\/s00431-023-05092-z","article-title":"Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy","volume":"182","author":"Li","year":"2023","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.dmd.2025.100090_bib20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00228-018-2600-8","article-title":"Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens","volume":"75","author":"Lin","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100090_bib21","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00228-016-2157-3","article-title":"Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy","volume":"73","author":"Lu","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100090_bib22","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2217\/pgs.14.186","article-title":"SCN1A, ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy","volume":"16","author":"Ma","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.dmd.2025.100090_bib23","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2165\/00003088-200342120-00002","article-title":"Clinical pharmacokinetics of oxcarbazepine","volume":"42","author":"May","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmd.2025.100090_bib24","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamaneurol.2022.3651","article-title":"Genetic testing to inform epilepsy treatment management from an international study of clinical practice","volume":"79","author":"McKnight","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.dmd.2025.100090_bib25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3389\/fphar.2016.00437","article-title":"Age-dependent hepatic UDP-glucuronosyltransferase gene expression and activity in children","volume":"7","author":"Neumann","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.dmd.2025.100090_bib26","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.dmd.2025.100090_bib27","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/01.ftd.0000179847.37965.4e","article-title":"Pharmacokinetic variability of new antiepileptic drugs at different ages","volume":"27","author":"Perucca","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.dmd.2025.100090_bib28","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00003088-200645040-00002","article-title":"Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age","volume":"45","author":"Perucca","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmd.2025.100090_bib29","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1212\/01.wnl.0000186800.18456.72","article-title":"Oxcarbazepine adjunctive therapy in infants and young children with partial seizures","volume":"65","author":"Pi\u00f1a-Garza","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.dmd.2025.100090_bib30","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1111\/bcp.13392","article-title":"Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children","volume":"83","author":"Rodrigues","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100090_bib31","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.seizure.2017.07.015","article-title":"Effects of ABCB1, ABCC2, UGT2B7 and HNF4\u03b1 genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy","volume":"51","author":"Shen","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.dmd.2025.100090_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1037239","article-title":"Pharmacogenetics-based population pharmacokinetic analysis and dose optimization of valproic acid in Chinese southern children with epilepsy: effect of ABCB1 gene polymorphism","volume":"13","author":"Shen","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.dmd.2025.100090_bib33","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/psp4.13151","article-title":"Population pharmacokinetic analysis for dose regimen optimization of vancomycin in Southern Chinese children","volume":"13","author":"Shen","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmd.2025.100090_bib34","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/epi.17241","article-title":"International league against epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE task force on nosology and definitions","volume":"63","author":"Specchio","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.dmd.2025.100090_bib35","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.dmpk.2014.12.002","article-title":"Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities","volume":"30","author":"Sugiyama","year":"2015","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmd.2025.100090_bib36","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1007\/s11095-012-0668-x","article-title":"A bodyweight-dependent allometric exponent for scaling clearance across the human life-span","volume":"29","author":"Wang","year":"2012","journal-title":"Pharm Res"},{"key":"10.1016\/j.dmd.2025.100090_bib37","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/aps.2014.76","article-title":"Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy","volume":"35","author":"Wang","year":"2014","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.dmd.2025.100090_bib38","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/bcpt.14000","article-title":"Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric patients with epilepsy: model-based dose optimization","volume":"134","author":"Wu","year":"2024","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.dmd.2025.100090_bib39","article-title":"Comparison of oxcarbazepine efficacy and MHD concentrations relative to age and BMI: associations among ABCB1, ABCC2, UGT2B7, and SCN2A polymorphisms","volume":"98","author":"Yang","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.dmd.2025.100090_bib40","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.addr.2011.12.003","article-title":"The transport of antiepileptic drugs by P-glycoprotein","volume":"64","author":"Zhang","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.dmd.2025.100090_bib41","doi-asserted-by":"crossref","first-page":"7709","DOI":"10.1080\/21655979.2022.2036916","article-title":"Effects of genetic polymorphism of drug-metabolizing enzymes on the plasma concentrations of antiepileptic drugs in Chinese population","volume":"13","author":"Zhao","year":"2022","journal-title":"Bioengineered"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625090993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625090993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:58:50Z","timestamp":1777474730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625090993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0090955625090993"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100090","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ABCC2 as a novel covariate influencing oxcarbazepine pharmacokinetics in pediatric epilepsy: Insights from population modeling","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100090"}}